Together, these results invoke that suppressing Piezo1-mediated mechanotransduction hinders proteolytic damage of the aorta and is likely to decelerate AAA growth in patients should such drug-based approach be brought to the clinical setting. Here, PIEZO1 is linked to triple-A syndrome.